AVEO Pharmaceuticals, Inc. (AVEO)
-NasdaqGS | Prev Close: | 2.66 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 3.25 |
|---|
| Beta: | 0.86 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 2.25 - 14.08 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 2,006,620 |
|---|
| Market Cap: | 136.39M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.57 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Life Science Industry Veteran Stephane Bancel Joins Flagship VenturesPR Newswire(Wed, May 22)
- Law Offices of Todd M. Garber Announces Investigation of AVEO Pharmaceuticals, Inc.Business Wire(Mon, May 20)
- Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- AVEOGlobeNewswire(Fri, May 17)
- Aveo Pharmaceuticals, Inc. Sued by InvestorPR Newswire(Fri, May 17)
- AVEO PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual MeetingBusiness Wire(Wed, May 15)
- Complete Seth Klarman And Baupost Group Portfolio Updateat Seeking Alpha(Wed, May 15)
- Aveo Screwed Up but Its Kidney Cancer Drug Is Realat TheStreet(Wed, May 15)
- Tracking Seth Klarman's Baupost Group Holdings - Q1 2013 Updateat Seeking Alpha(Wed, May 15)
- Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.Business Wire(Tue, May 14)
- The Law Offices of Marc S. Henzel Announces Class Action Lawsuit Against Aveo Pharmaceuticals, Inc. and Certain Officers -- (Nasdaq: AVEO) was filed on behalf of stockholdersPR Newswire(Tue, May 14)
- Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against AVEO Pharmaceuticals, Inc.Business Wire(Tue, May 14)
- SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $150,000 From Investment in AVEO Pharmaceuticals, Inc. to Contact Brower Piven Before the July 8, 2013 Lead Plaintiff Deadline -- AVEOGlobeNewswire(Mon, May 13)
- Billionaire Seth Klarman's Long-Term Stock Picksat Seeking Alpha(Mon, May 13)
- Seth Klarman's Worst Performing Stock Picks Year-To-Dateat Seeking Alpha(Mon, May 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 7.27 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.35 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.57 |
|---|
| Mean Recommendation*: | 3.1 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, operates as a cancer therapeutics company. The company engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform.
View More 
0.52%